Transcriptome changes induced by epstein-barr virus LMP1 and LMP2A in transgenic lymphocytes and lymphoma

mBio

Volumn 3, Issue 5, 2012, Pages

  Shair, Kathy H Y ^a,c   Raab Traub, Nancy ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868342582     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00288-12     Document Type: Article

References (40)

1. Miller WE, Cheshire JL, Raab-Traub N. 1998. Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the la-tent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol. Cell. Biol. 18: 2835-2844.
2. Mosialos G, et al. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399.
3. Panagopoulos D, Victoratos P, Alexiou M, Kollias G, Mosialos G. 2004. Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo. J. Virol. 78:13253-13261.
4. Raab-Traub N. 2002. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12:431-441.
5. Uchida J, et al. 1999. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science (New York, NY) 286:300-303.
6. Caldwell RG, Brown RC, Longnecker R. 2000. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J. Virol. 74:1101-1113.
7. Miller CL, Longnecker R, Kieff E. 1993. Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J. Virol. 67:3087-3094.
8. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. 1998. Epstein-Barr virus LMP2A drives B cell development and survivalinthe absence of normal B cell receptor signals. Immunity 9:405-411.
9. Chaganti S, et al. 2005. Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 106:4249-4252.
10. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. 2005. Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106:4339-4344.
11. Miller CL, Lee JH, Kieff E, Longnecker R. 1994. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc. Natl. Acad. Sci. U. S. A. 91:772-776.
12. Allen MD, Young LS, Dawson CW. 2005. The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J. Virol. 79:1789-1802.
13. Fotheringham JA, Mazzucca S, Raab-Traub N. 2010. Epstein-Barr virus latent membrane protein-2A-induced DeltaNp63alpha expression is associated with impaired epithelial-cell differentiation. Oncogene 29: 4287-4296.
14. Lu J, et al. 2006. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J. Biol. Chem. 281:8806-8814.
15. Morrison JA, Raab-Traub N. 2005. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J. Virol. 79:2375-2382.
16. Scholle F, Bendt KM, Raab-Traub N. 2000. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74:10681-10689.
17. Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N. 2004. Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lym-phoma. Cancer Res. 64:5251-5260.
18. Portis T, Cooper L, Dennis P, Longnecker R. 2002. The LMP2A signa-losome-a therapeutic target for Epstein-Barr virus latency and associated disease. Front. Biosci. 7:d414-d426.
19. Kulwichit W, et al. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 95:11963-11968.
20. Shair KH, et al. 2007. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog. 3:e166. http://dx.doi.org/10.1371/journal.ppat.0030166.
21. Zhang B, et al. 2012. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148: 739-751.
22. Thornburg NJ, et al. 2006. LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Oncogene 25:288-297.
23. Morrison JA, Klingelhutz AJ, Raab-Traub N. 2003. Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J. Virol. 77: 12276 -12284.
24. Pegtel DM, et al. 2005. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyn-geal carcinoma metastasis. J. Virol. 79:15430-15442.
25. Portis T, Dyck P, Longnecker R. 2003. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102:4166-4178.
26. Portis T, Longnecker R. 2003. Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J. Virol. 77:105-114.
27. Stunz LL, et al. 2004. Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture. Immunity 21:255-266.
28. Swanson-Mungerson M, Bultema R, Longnecker R. 2006. Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro. J. Virol. 80:6764-6770.
29. Swanson-Mungerson M, Longnecker R. 2007. Epstein-Barr virus latent membrane protein 2A and autoimmunity. Trends Immunol. 28:213-218.
30. Muramatsu M, et al. 2000. Class switch recombination and hypermuta-tion require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553-563.
31. Adler B, et al. 2002. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc. Natl. Acad. Sci. U. S. A. 99:437-442.
32. Feng WH, et al. 2007. ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J. Virol. 81:10113-10122.
33. Yu X, Wang Z, Mertz JE. 2007. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog. 3:e194. http://dx.doi.org/10.1371/journal.ppat.0030194.
34. Cahir-McFarland ED, et al. 2004. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J. Virol. 78:4108-4119.
35. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. 2000. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc. Natl. Acad. Sci. U. S. A. 97:6055-6060.
36. Feuillard J, et al. 2000. Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. Blood 95:2068-2075.
37. Vrazo AC, Chauchard M, Raab-Traub N, Longnecker R. 2012. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice. PLoS Pathog. 8:e1002662. http://dx.doi.org/doi:10.1371/journal.ppat.1002662.
38. Vockerodt M, et al. 2008. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centreB cells towardsaHodg-kin's Reed-Sternberg-like phenotype. J. Pathol. 216:83-92.
39. Swart R, Ruf IK, Sample J, Longnecker R. 2000. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway. J. Virol. 74:10838-10845.
40. Shair KH, et al. 2012. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) and LMP2A function cooperatively to promote carcinoma development in a mouse carcinogenesis model. J. Virol. 86:5352-5365.